Piper Sandler initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $72 price target The firm thinks Monopar’s two distinct therapeutic pursuits represent value potential far exceeding the company’s current market cap. While these two programs – radiotherapeutics utilizing a unique new oncology target and a small molecule copper mobilizer with “impressive” proof of concept data in Wilson disease – “are quite disparate,” they collectively represent meaningful upside to current levels, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025
- Monopar Therapeutics prices 798,655 shares at $23.79 in registered offering
- Monopar Therapeutics Achieves Milestone in Cancer Treatment
- Monopar Therapeutics doses first patient with MNPR-101-Lu
- Monopar Therapeutics price target raised to $37 from $9 at JonesResearch
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue